No Data
No Data
Insider Purchase: Director at $RNAC Buys 14,740 Shares
Cartesian Therapeutics Director Timothy Springer Buys Over $1.37 Million in Stock
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27%
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40
Oppenheimer Maintains Cartesian Therapeutics(RNAC.US) With Hold Rating
Cantor Fitzgerald Upgrades Cartesian Therapeutics(RNAC.US) to Buy Rating, Maintains Target Price $22
Unlock the Full List